Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Device and methods for targeted tissue drug delivery

A technology for drug delivery and drug application in the field of new minimally invasive implantable devices, which can solve the problems of long-term serious demand for chronic atrial fibrillation and other problems

Active Publication Date: 2015-12-09
NATIVE CARDIOCASCULAR
View PDF7 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Significant and long-standing need for new modalities in the treatment of chronic atrial fibrillation remains unaddressed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Device and methods for targeted tissue drug delivery
  • Device and methods for targeted tissue drug delivery
  • Device and methods for targeted tissue drug delivery

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0233] In this example, it is shown that the present invention can be effectively used for the targeted local administration of amiodarone, sulfasulfone and procainamide directly to cardiac tissue by traditional methods after surgery. In this example, Table 1 below lists the drugs, post-operative oral and intravenous doses (traditional therapy administration), and, for comparison, all used in the target tissue administration form of therapy using the device of the present invention. dose. As shown in Table 1, when the present invention is used for targeted drug delivery, the medication required for treatment is significantly reduced, which also means that when the present invention is used, systemic toxicity is significantly reduced.

[0234] It should be understood that Table 1 depicts representative drugs and dosages used in certain embodiments of the invention for purposes of illustration only. In no case should Table 1 be construed as limiting the scope of the invention. ...

Embodiment 2

[0238] In one experiment, two groups of pigs were used to determine the difference between intrapericardial (IPC) versus intravenous (IV) administration of the antiarrhythmic drug procainamide. Intrapericardial (n=6) or intrapericardial (n=7) administration with continuous intravenous doses of 2, 8, 16 mg / kg (cumulative 2, 10, 26 mg / kg), or continuous intrapericardial doses of 0.5 , 1, 2mg / kg (cumulative 0.5, 1.5, 3.5mg / kg). Each dose was resuspended in 10ml and administered at a rate of 1mL / min. The pharmacokinetics of both drug administrations were statistically significant. Peak drug concentrations obtained with intrapericardial administration were in the range of 250-900 μg / ml, while measurable levels in plasma were low (<1 μg / ml). Peak plasma concentrations obtained with intravenous administration range from <1 to 40 μg / ml, but concentrations in pericardial fluid are equivalent to those in plasma. It should be noted that pericardial fluid concentrations during intraven...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Representative embodiments of the present invention provide for novel, minimally invasive implantable devices and methods for targeted tissue drug delivery of cardiovascular drugs.

Description

[0001] Cross References to Related Applications [0002] This PCT International Application claims US Provisional Patent Application 61 / 743,759, filed September 11, 2012, and US Provisional Patent Application 61749,13, filed January 7, 2013, which are hereby incorporated by reference in their entirety. technical field [0003] The main subject of the present invention relates to novel minimally invasive implantable devices and methods for target tissue drug delivery. Background technique [0004] Heart rhythm disturbances, such as atrial fibrillation, are common. The current treatment measures for patients are usually drug therapy and / or electroshock conversion. Conventional drug therapy for heart rhythm disturbances often fails, requiring conversion using electric shocks. Shock conversion requires a lot of energy, and maintaining sinus rhythm using this method has proven difficult. In addition, there are other problems with traditional methods used to treat patients with...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61N1/39
CPCA61M25/0023A61M2025/0004A61N1/0587A61N1/0595A61N1/0597A61M31/00A61N1/3962A61M19/00A61N1/0476A61N1/046
Inventor 扬·D·金约瑟夫·V·培高利兹斯考特·约翰逊
Owner NATIVE CARDIOCASCULAR
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com